Cytokinetics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Cytokinetics Contact Number

Cytokinetics Muscle Biology Therapies Contact Us

6 hours ago Cytokinetics.com Show details

Category: Contact SupportShow more

CYTOKINETICS 280 E Grand Ave, South San Francisco, CA

7 hours ago Yelp.com Show details

(650) 624-3000

Business website. cytokinetics.com. Phone number. (650) 624-3000. Get Directions. 280 E Grand Ave South San Francisco, CA 94080.

Category: Contact NumberShow more

Cytokinetics, Inc. South San Francisco, Ca

7 hours ago Bizmgr.salespider.com Show details

Cytokinetics, Inc. is located at 280 East Grand Avenue, South San Francisco, Ca. View company information, address & phone number

Category: Contact NumberShow more

Cytokinetics Muscle Biology Therapies Home

5 hours ago Cytokinetics.com Show details

Cytokinetics is committed to our mission of developing potential medicines that may improve the healthspan of people living with cardiovascular and neuromuscular diseases of impaired muscle function. Cytokinetics is proud to be recognized as one of the 2021 Best Places to Work in the Bay Area by the San Francisco Business Times.

Category: Home PhoneShow more

Cytokinetics Crunchbase Company Profile & Funding

6 hours ago Crunchbase.com Show details

Contact Email [email protected]cytokinetics.com Phone Number 6506243010 Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and

Founded: Jul 01, 2007
Location: South San Francisco, California

Category: Contact NumberShow more

Edward Robbie Email, Phone Manager, Clinical

1 hours ago Adapt.io Show details

Find Edward Robbie's accurate email address and contact/phone number in Adapt.io. Currently working as Manager, Clinical Operations at Cytokinetics in California, United States.

Category: Phone NumberShow more

CYTOKINETICS, INCORPORATED :: Vermont (US) :: OpenCorporates

Just Now Opencorporates.com Show details

Free and open company data on Vermont (US) company CYTOKINETICS, INCORPORATED (company number 0395331), 280 East Grand …

Category: Contact NumberShow more

Cytokinetics Corporate Headquarters, Office Locations and

9 hours ago Craft.co Show details

Cytokinetics is headquartered in South San Francisco, CA and has 1 office location across 1 country. See the full list at Craft.

Category: Contact NumberShow more

Cytokinetics Facebook

1 hours ago Facebook.com Show details

Cytokinetics, South San Francisco, California. 365 likes · 31 talking about this · 89 were here. We are developing potential medicines to improve the healthspan of people with devastating

Category: Contact NumberShow more

EIN 943291317 Cytokinetics Inc, South San Francisco

6 hours ago Eintaxid.com Show details

Cytokinetics Inc is a corporation in South San Francisco, California. The employer identification number (EIN) for Cytokinetics Inc is 943291317. EIN for organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS Number. It is one of the corporates which submit 10-K filings with the SEC. Basic Profile

Category: Contact NumberShow more

Cytokinetics Announces Fourth Annual Communications

3 hours ago Cytokineticsinc.gcs-web.com Show details

(415) 290-7757

Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact: Diane Weiser Senior Vice President, Corporate Communications, Investor Relations (415) 290-7757 Source: Cytokinetics, Incorporated

Category: Contact NumberShow more

Connections null Email, Phone Executive Vice President

9 hours ago Adapt.io Show details

Find Connections 's accurate email address and contact/phone number in Adapt.io. Currently working as Executive Vice President, Research and Development at Cytokinetics in California, United States.

Category: Phone NumberShow more

Annual Report & Proxy Cytokinetics, Inc.

3 hours ago Ir.cytokinetics.com Show details

Cytokinetics' Annual Stockholders' Meeting will be held on Wednesday, May 12, 2021, at 10:30 a.m. local time, at Cytokinetics, located at 280 East Grand Avenue, South San Francisco, CA 94080. 2020 Annual Report. 04/19/21. ( FY ) 2020 Annual Report. 1.8 MB. 2021 Notice of Annual Meeting and Proxy Statement. 04/19/21.

Category: Contact NumberShow more

Cytokinetics – Reldasemtiv

5 hours ago Als-mnd.org Show details

Cytokinetics is a company that was founded in 1997 to develop treatments targeting impairments in muscle function. Cytokinetics has recently tested reldesemtiv after previously working on their initial ALS drug tirasemtiv. Tirasemtiv showed promising results in a Phase 2 clinical trial (BENEFIT-ALS) in 2014, and was followed by a phase 3

Category: Contact NumberShow more

Cytokinetics to Host Investor Call and Webcast to Discuss

5 hours ago Finance.yahoo.com Show details

(415) 290-7757

Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Communications, Investor Relations (415) 290-7757. Related Quotes. Symbol Last Price Change % Change; CYTK. Cytokinetics

Category: Contact NumberShow more

Cytokinetics, Inc. (CYTK) Company Profile & Overview

6 hours ago Stockanalysis.com Show details

Company profile for Cytokinetics, Inc. (CYTK) with a description, list of executives, contact details and other key facts. Company profile for Cytokinetics, Inc. (CYTK) with a description, list of executives, contact details and other key facts. CUSIP Number: 23282W100: ISIN Number: US23282W6057: Employer ID: 94-3291317: Key Executives

Category: Contact NumberShow more

Cytokinetics Announces Fourth Annual Communications

7 hours ago Globenewswire.com Show details

Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact

Category: Contact NumberShow more

Cytokinetics Announces Presentation of Results From

2 hours ago Cytokineticsinc.gcs-web.com Show details

(415) 290-7757

For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission. Contact: Cytokinetics Diane Weiser Vice President, Corporate Communications, Investor Relations (415) 290-7757. Source: Cytokinetics, Incorporated

Category: Contact NumberShow more

Jobs with Cytokinetics, Inc. BioSpace

9 hours ago Biospace.com Show details

Cytokinetics to Announce Second Quarter Results on August 5, 2021. 7/22/2021. Cytokinetics, Incorporated announced that it is scheduled to report second quarter results on August 5, 2021 at 4:00 PM Eastern Time. Cytokinetics Announces Pricing of Public Offering of Common Stock - July 21, 2021. 7/21/2021

Category: Contact NumberShow more

Cytokinetics Announces Positive Topline Results of RedwoodHCM

3 hours ago Finance.yahoo.com Show details

CK-274 is designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle and consequently reduce myocardial contractility. About Cytokinetics. Contact

Category: Contact NumberShow more

PRESENTATIONS Cytokinetics, Inc.

6 hours ago Ir.cytokinetics.com Show details

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance.

Category: Contact NumberShow more

CYTK Company Profile for CYTOKINETICS, INCORPORATED

1 hours ago Msn.com Show details

Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for

Category: Contact NumberShow more

Cytokinetics Incorporated : Outlines GoToMarket Strategy

Just Now Marketscreener.com Show details

(425) 314-1721

For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission. Contact: Cytokinetics Joanna Siegall Senior Manager, Corporate Communications, Investor Relations (425) 314-1721. References

Category: Contact NumberShow more

Where Cytokinetics Stands With Analysts Cytokinetics

5 hours ago Benzinga.com Show details

In the last 3 months, 6 analysts have offered 12-month price targets for Cytokinetics. The company has an average price target of $53.17 with a high of $75.00 and a low of $40.00. Below is a

Category: Contact NumberShow more

John T. Henderson Net Worth, Biography & Insider Trading

9 hours ago Insidertrades.com Show details

John T. Henderson, M.D., Ch.B. has served as a member of our Board of Directors since February 2009. Since December 2000, Dr. Henderson has served as a consultant to the pharmaceutical industry as president of Futurepharm LLC. Dr. Henderson consulted for NeuroVia Inc. as Chief Development Officer and was an Executive Officer of this privately held company until October 2018.

Category: Contact NumberShow more

Cytokinetics Inc Sample Contracts Law Insider

9 hours ago Lawinsider.com Show details

cytokinetics inc – contract. this warrant and the shares issuable hereunder have not been registered under the securities act of 1933, as amended (the “act”), or the securities laws of any state and, except as set forth in sections 5.3 and 5.4 below, may not be offered, sold, pledged or otherwise transferred unless and until registered under said act and laws or, in the opinion of legal

Category: Contact NumberShow more

CY 6022 is an Open Label Study to Collect Longterm Safety

7 hours ago Clinicaltrials.gov Show details

You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. CY 6022 is an Open Label Study to Collect Long-term Safety and Tolerability Data for CK-3773274

Category: Contact NumberShow more

Cytokinetics Announces Positive Topline Results of

4 hours ago Globenewswire.com Show details

CK-274 is designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle and consequently reduce myocardial contractility. About Cytokinetics. Contact

Category: Contact NumberShow more

Cytokinetics (NASDAQ:CYTK) Earns "Buy" Rating from HC

6 hours ago Marketbeat.com Show details

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. grew its stake in Cytokinetics by 2.7% during the first quarter. BlackRock Inc. now owns 11,927,444 shares of the biopharmaceutical company's stock worth $277,433,000 after buying an additional 316,365 shares in the last quarter.

Category: Contact NumberShow more

Robert I. Blum Net Worth, Biography & Insider Trading History

6 hours ago Insidertrades.com Show details

(650) 624-3000

How do I contact Robert I. Blum? The corporate mailing address for Mr. Blum and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]cytokinetics.com.

Category: Contact NumberShow more

Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese

1 hours ago Clinicaltrials.gov Show details

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02695420

Category: Contact NumberShow more

Is Cytokinetics Incorporated (NASDAQ:CYTK) still hot stock

Just Now Baxterreport.com Show details

The total number of common shares currently owned by the public is 71.75 million. CYTK does have institutional investors; and they hold 93.80% of the stock. Cytokinetics Incorporated – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 14 new insider purchases involving 32,040 shares.

Category: Contact NumberShow more

Cytokinetics, Incorporated (NASDAQ:CYTK) to Post Q3 2021

3 hours ago Marketbeat.com Show details

CYTK has been the topic of a number of other research reports. JMP Securities raised their price target on shares of Cytokinetics from $26.00 to $44.00 and gave the company an "outperform" rating in a report on Monday, July 19th.

Category: Contact NumberShow more

Cytokinetics Incorporated (CYTK): The stock medium term

3 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 71.75 million. CYTK does have institutional investors; and they hold 93.90% of the stock. Cytokinetics Incorporated – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 19 new insider purchases involving 33,587 shares.

Category: Contact NumberShow more

Is Cytokinetics, Inc. (CYTK) a Winner in the Biotechnology

7 hours ago Investorsobserver.com Show details

Cytokinetics, Inc. (CYTK) stock is trading at $37.20 as of 11:56 AM on Tuesday, Oct 5, a gain of $0.81, or 2.21% from the previous closing price of $36.39. The stock has traded between $36.64 and $37.97 so far today.

Category: Tech SupportShow more

Cytokinetics Incorporated : Reports Second Quarter 2021

3 hours ago Marketscreener.com Show details

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2021. Net loss for the second quarter was $61.6 million, or $0.86 per share, compared to net loss for the second quarter of 2020 of $40.8 million, or $0.68 per share.

Category: Contact NumberShow more

Cytokinetics Announces Inducement Grants Under Nasdaq

5 hours ago Sg.finance.yahoo.com Show details

SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 30, 2021 it granted stock options to purchase an aggregate of 90,000 shares of common stock to twelve new employees whose employment commenced in June 2021 as a material inducement to their employment. The grant was previously …

Category: Contact NumberShow more

Cytokinetics Wikipedia

2 hours ago En.wikipedia.org Show details

Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998. Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins.

Category: Contact NumberShow more

Cytokinetics, Incorporated (CYTK) CEO Robert Blum on Q2

1 hours ago Seekingalpha.com Show details

Cytokinetics, Incorporated (NASDAQ:CYTK) Q2 2021 Earnings Conference Call Aug 5, 2021 4:30 PM ET Company Participants Diane Weiser - Senior Vice President of Corporate Communications and

Category: Contact NumberShow more

Cytokinetics Announces Fourth Annual Communications

8 hours ago Biospace.com Show details

Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact: Diane Weiser

Category: Contact NumberShow more

The ALS Association Golden West Chapter

Just Now Webgw.alsa.org Show details

Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact: Cytokinetics Diane Weiser

Category: Contact NumberShow more

Cytokinetics Announces Positive Topline Results of Redwood

4 hours ago Cardiacvascularnews.com Show details

(706) 679-3078

The webcast can be accessed through the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (international) and typing in the passcode 2984784.

Category: Contact NumberShow more

Cytokinetics Announces Cohort 3 of REDWOODHCM is Open to

8 hours ago Nz.finance.yahoo.com Show details

Next Cohort to Enroll Patients on Background Therapy of DisopyramideSOUTH SAN FRANCISCO, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 3 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase 2 clinical trial of CK …

Category: Contact NumberShow more

Cytokinetics Announces Progression of REDWOODHCM to

6 hours ago Benzinga.com Show details

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ: CYTK) today announced the progression of REDWOOD-HCM following the conduct of an interim analysis

Category: Contact NumberShow more

Cytokinetics (CYTK) Reports Q2 Loss, Misses Revenue

1 hours ago Nasdaq.com Show details

Cytokinetics (CYTK) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss …

Category: Contact NumberShow more

Fady Malik South San Francisco, California, United

7 hours ago Linkedin.com Show details

Executive Vice President, Research and Development at Cytokinetics South San Francisco, California, United States 500+ connections. Join to Connect Report this profile Contact Fady directly

Title: Executive Vice President, …
Location: South San Francisco, California, United States
1. 500+ connections

Category: Contact NumberShow more

Is Cytokinetics Incorporated (CYTK) a Keeper? – News Heater

7 hours ago Newsheater.com Show details

Cytokinetics Incorporated (NASDAQ:CYTK) went down by -3.44% from its latest closing price compared to the recent 1-year high of $34.32. The company’s stock price has collected -8.99% of loss in the last five trading sessions. Press Release reported on 09/08/21 that Cytokinetics

Category: Contact NumberShow more

Phase 3 ALS study (CY 5031) with reldesemtiv. (Cytokinetics)

5 hours ago Gwdocs.com Show details

Phase 3 ALS study (CY 5031) with reldesemtiv. (Cytokinetics) Neurology. This is a Phase 3, double-blind, randomized, placebo-controlled trial of reldesemtiv in patients aged 18 to 80 with ALS to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of company is cytokinetics inc?

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

What does cytokinetics do in the bay area?

Cytokinetics is committed to our mission of developing potential medicines that may improve the healthspan of people living with cardiovascular and neuromuscular diseases of impaired muscle function. Cytokinetics is proud to be recognized as one of the 2021 Best Places to Work in the Bay Area by the San Francisco Business Times.

What kind of drug is cytokinetics ck 3773274?

Cytokinetics is developing CK-3773274 (CK-274), an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM). The drug’s Phase 1 trial, which assessed the safety and tolerability of single and multiple oral doses, started in December 2018.

What did cytokinetics get for omecamtiv mecarbil?

In February 2017 Cytokinetics sold to Royalty Pharma a 4.5 percent royalty on potential worldwide sales of omecamtiv mecarbil for $90 million in an upfront cash payment. Results from the drug's Phase 2 clinical trial, COSMIC-HF, showed that omecamtiv mecarbil improved several measures of cardiac function in people with chronic heart failure.

Brand New Updated

Popular Brands

Costco
Cisco
Ccu
Cae